A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Hereditary Angioedema

Interventions

BIOLOGICAL: Recombinant human C1 inhibitor
OTHER: Placebo

Sponsor

Pharming Technologies B.V.